These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://matteoeqxe317144.blogolenta.com/36153577/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide